GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Incannex Healthcare Ltd (STU:IQI) » Definitions » EBIT

Incannex Healthcare (STU:IQI) EBIT : €-14.14 Mil (TTM As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Incannex Healthcare EBIT?

Incannex Healthcare's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was €-5.61 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was €-14.14 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Incannex Healthcare's annualized ROC % for the quarter that ended in Mar. 2024 was -472.07%. Incannex Healthcare's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -2,493.39%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Incannex Healthcare's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -71.95%.

Incannex Healthcare EBIT Historical Data

The historical data trend for Incannex Healthcare's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incannex Healthcare EBIT Chart

Incannex Healthcare Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.01 -1.73 -2.53 -7.12 -9.62

Incannex Healthcare Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.49 -3.71 - -4.82 -5.61

Competitive Comparison of Incannex Healthcare's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Incannex Healthcare's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Incannex Healthcare's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Incannex Healthcare's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Incannex Healthcare's EV-to-EBIT falls into.


Incannex Healthcare EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-14.14 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Incannex Healthcare  (STU:IQI) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Incannex Healthcare's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=-22.428 * ( 1 - 0% )/( (4.39 + 5.112)/ 2 )
=-22.428/4.751
=-472.07 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=20.503 - 2.767 - ( 13.346 - max(0, 2.922 - 19.561+13.346))
=4.39

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=15.87 - 2.197 - ( 8.561 - max(0, 2.635 - 15.013+8.561))
=5.112

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Incannex Healthcare's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-22.428/( ( (0.942 + max(-1.678, 0)) + (0.857 + max(-2.101, 0)) )/ 2 )
=-22.428/( ( 0.942 + 0.857 )/ 2 )
=-22.428/0.8995
=-2,493.39 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 1.089) - (2.767 + 0 + 4.4408920985006E-16)
=-1.678

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.386) - (2.197 + 0 + 0.29)
=-2.101

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Incannex Healthcare's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=-14.139/19.650
=-71.95 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Incannex Healthcare EBIT Related Terms

Thank you for viewing the detailed overview of Incannex Healthcare's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Incannex Healthcare (STU:IQI) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Incannex Healthcare Ltd (STU:IQI) » Definitions » EBIT
Comparable Companies
PNXP CYTH BGXX DRRX RMTI QLI CPIX INIS SHWZ TXMD ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ VTRS SZSE:000538 NBIX
Traded in Other Exchanges
IXHL:USA
Address
8 Century Circuit Norwest, Suite 105, Sydney, NSW, AUS, 3000
Website
https://www.incannex.com.au
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products.